Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Proteins: From Genes to Degradation02:11

Proteins: From Genes to Degradation

14.2K
Within a biological system, the DNA encodes the RNA, and the nucleotide sequence in the RNA further defines the amino acid sequence in the protein. This is referred to as “The Central Dogma of Molecular Biology” - a term coined by Francis Crick.  Central dogma is a firm principle in biology that defines the flow of genetic information within any life form. The two fundamental steps in central dogma are - transcription and translation.
Transcription is the synthesis of RNA...
14.2K
Proteins: From Genes to Degradation02:11

Proteins: From Genes to Degradation

4.3K
4.3K
Regulated Protein Degradation02:58

Regulated Protein Degradation

8.8K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.8K
Regulated Protein Degradation02:58

Regulated Protein Degradation

3.1K
3.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

11.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.2K
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

3.3K
Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors.

Journal of medicinal chemistry·2026
Same author

USP22 is a novel vulnerability regulating MEIS1 protein abundance and gene transcription in KMT2Ar acute leukemia.

Blood·2026
Same author

AURORA A interacts with DICER and SETD2 to promote S-phase progression.

EMBO reports·2026
Same author

On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.

Journal of medicinal chemistry·2026
Same author

Development of a Brain-Penetrant Nurr1 Agonist Tool.

ChemMedChem·2026
Same author

p21-Activated Kinase (PAK) Group I-Targeting Inhibitors Promote the Dimeric Conformation in Live Cells.

ACS chemical biology·2026

関連する実験動画

Updated: Jan 24, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K

Click. Screen. Degrade. A Miniaturized D2B Workflow for Rapid PROTAC Discovery

Marko Mitrović1,2, Francesco Aleksy Greco1,2,3, Yiliam Cruz García4

  • 1Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, Frankfurt am Main 60438, Germany.

Journal of medicinal chemistry
|January 23, 2026
PubMed
まとめ

この研究では、プロテオリシス誘導性キメラ（PROTAC）の合成と評価のための新しいワークフローを紹介します。直接生物アプローチは、精製ステップを回避することにより、標的タンパク質分解剤の発見を加速します。

キーワード:
プロタック創薬ハイスループット合成直接生物評価標的タンパク質分解剤

さらに関連する動画

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K

関連する実験動画

Last Updated: Jan 24, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.7K

科学分野:

  • 医薬品化学
  • 化学生物学
  • 創薬

背景:

  • 標的タンパク質分解は急速に進歩している分野です。
  • 合理的な設計方法論の欠如により、プロテオリシス誘導性キメラ（PROTAC）の開発は困難です。
  • 現在の方法では、しばしば長い合成と精製プロセスが含まれます。

研究 の 目的:

  • PROTAC合成と評価のための合理化されたワークフローを開発すること。
  • 従来のPROTAC開発の限界を克服すること。
  • PROTAC候補の迅速な同定と最適化を可能にすること。

主な方法:

  • ハイスループット、半自動合成と直接細胞アッセイ評価を組み合わせた直接生物アプローチ。
  • ナノモルスケールでの効率的なPROTAC合成のための銅触媒アジド-アルキン環化付加を利用。
  • 化合物精製ステップを回避するワークフローの実装。

主要な成果:

  • 4つの多様なターゲットにわたるワークフローの一般的な適用可能性を実証しました。
  • 5μLという低反応量でPROTAC合成を達成しました。
  • 数日以内に数百のPROTACの合成と評価を可能にしました。

結論:

  • 開発されたワークフローは、PROTACの発見と開発を大幅に加速します。
  • このアプローチは、包括的なターゲット分解能評価とE3リガーゼ選択を容易にします。
  • この方法論は、標的タンパク質分解戦略を進歩させるための強力なツールを提供します。